Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2022—Abbott announced that a study published in Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how a person will recover from traumatic brain injury (TBI) (Korley FK, et al. Lancet Neurol. 2022;21[9]:803–813).
August 2022—CorePath Laboratories announced a partnership with U.K.-based diagnostics developer Cizzle Biotech to develop and offer a proprietary early-stage lung cancer test throughout the United States. Cizzle Biotech’s proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, Cizzle Biotech says, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
August 2022—BD has unveiled its BD FACSDiscover S8 Cell Sorter with BD CellView Image Technology, which captures images of individual cells flowing through the system and sorts them based on detailed microscopic image analysis of each one at high sort speeds.
August 2022—Roche has launched its BenchMark Ultra Plus tissue staining platform. The system was built on the technology of the BenchMark Ultra and uses improved Ventana system software, which aims to enhance quality control and inventory management.
August 2022—Bio-Rad Laboratories launched two new Exact Diagnostics products. The Exact Diagnostics Synthetic Negative Run Control is screened negative for nine targets, Anaplasma phagocytophilum, Babesia microti, Bartonella quintana, Borrelia burgdorferi, Ehrlichia chaffeensis, enterovirus coxsackievirus A9, HSV-1 and HSV-2, and varicella zoster virus. The Exact Diagnostics HAI Negative Run Control is screened negative for Clostridium difficile, methicillin-resistant Staphylococcus aureus, and methicillin-susceptible Staphylococcus aureus.
August 2022—Thermo Fisher Scientific announced an agreement with Inpeco S.A. to develop connectivity between the Thermo Scientific Cascadion SM automated liquid chromatography mass spectrometer and the Inpeco S.A. FlexLab total laboratory automation system.
August 2022—Beckman Coulter and Scopio Labs announced a worldwide partnership to accelerate the adoption of Scopio’s next-generation peripheral blood smear platforms. Scopio’s technology uses full-field imaging and AI decision support to eliminate manual microscopy.
August 2022—Bio-Rad Laboratories has launched the CFX Duet Real-Time PCR system to support researchers in developing singleplex and duplex quantitative PCR assays. The CFX Duet system offers the robust thermal performance and proprietary, accurate optical shuttle system of the company’s CFX Opus system. It is a two-color system that is factory calibrated for common dyes and allows the quantification of up to two targets in genotyping and multiple gene expression analyses without the need for passive reference dyes. An additional fluorescence resonance energy transfer mode supports protein melt analysis for basic protein characterization.
August 2022—Thermo Fisher Scientific has launched its Applied Biosystems TaqPath Respiratory Viral Select panel. The CE-IVD-marked molecular assay panel provides results in approximately three hours and tests for adenovirus, human metapneumovirus, rhinovirus/enterovirus, and parainfluenza virus using PCR technology. RNase P and positive controls are included to offer sample-to-result reliability. The solution is scalable, allowing laboratories to run from one to 94 samples simultaneously.
August 2022—Verichem Laboratories now offers a range of liquid-stable and ready-to-use biosynthetic clinical reference materials for use with urine chemistry assays and designed for system calibration and calibration verification testing on a variety of clinical testing platforms, including from Abbott, Beckman Coulter, Roche, and Siemens Healthineers.
